BOTOX + Placebo for BOTOX
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Conditions
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Trial Timeline
Mar 29, 2022 → Dec 6, 2024
NCT ID
NCT05141006About BOTOX + Placebo for BOTOX
BOTOX + Placebo for BOTOX is a phase 2 stage product being developed by AbbVie for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The current trial status is completed. This product is registered under clinical trial identifier NCT05141006. Target conditions include Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).
What happened to similar drugs?
1 of 5 similar drugs in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) were approved
Approved (1) Terminated (2) Active (3)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06137287 | Phase 3 | Completed |
| NCT05216250 | Phase 2 | Completed |
| NCT05141006 | Phase 2 | Completed |
Competing Products
20 competing products in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)